Assessment of metabolic markers of cardiorenal disorders in patients with arterial hypertension and metabolic syndrome

Introduction. Cardiorenal disorders (CRN) in arterial hypertension (AH) occur with interdependent dysfunction of the cardiovascular and renal systems. The concept of cardio-reno-metabolic health (CRMH) defines a dependent relationship between the clinical and pathogenetic manifestations of heart and kidney diseases in patients with metabolic disorders (MN).

Aim. To study the metabolic markers of CRN in patients with hypertension and in combination with metabolic syndrome (MS).

Materials and methods. The functions of the heart, kidneys, and lipid profile were studied in patients aged 40 to 69 years with hypertension and with hypertension in combination with MS.

Results. The average eGFR values (estimated glomerular filtration rate) based on cystatin C are 53,5% lower than those based on creatinine (p = 0.0001). Patients with hypertension combined with MS were 42.7% more likely to have chronic kidney disease (CKD) C3aA2, 21.2% more likely to have C3bA2; the level of highly sensitive C–reactive protein (hs-CRP) was 42.8% higher compared with patients with hypertension without MN (p = 0.0001). Cystatin C values positively correlate with systolic blood pressure (SAD); eGFR has a negative association with SAD in both groups (p < 0.05). The presence of chronic heart failure with a low ejection fraction (CHF) in combination with chronic kidney disease (CKD) with moderate (C3a A2) and significantly reduced (C3b A2) renal function allows us to state the presence of CRN in 13.3% of patients with hypertension and in 17.7% of patients with hypertension combined with MS (p = 0.0001). Dyslipidemia and atherogenic lipid levels are 122% higher in patients with hypertension combined with MS, hyperlipoproteinemia (a) is 79% more common in patients with CRN on the background of MN (p = 0.0001).

Conclusion. Elevated lipoprotein (a) (LP (a)) concentrations and dyslipidemia in patients with hypertension are associated with cardiorenal and metabolic disorders.

1. Shalnova SA, Kapustina AV, Deev AD, Balanova YuA. Factors associated with cause-specific death in Russia. Data from longitudinal prospective study 1977–2001. Rational Pharmacotherapy in Cardiology. 2019;15(1):4–16. (In Russ.) https://doi.org/10.20996/1819-6446-2019-15-1-4-16.

2. Reznik EV, Nikitin IG. Cardiorenal syndrome in patients with heart failure as a stage of the cardiorenal continuum (part 1): definition, classification, pathogenesis, diagnosis, epidemiology (literature review). Russian Archive of Internal Medicine. 2019;9(1):5–22. (In Russ.) https://doi.org/10.20514/2226-6704-2019-9-1-5-22.

3. Smirnov AV, Dobronravov VA, Kayukov IG. Cardiorenal continuum, pathogenetical grounds of preventive nephrology. Nephrology (Saint-Petersburg). 2005;9(3):7–15. (In Russ.) Available at: https://journal.nephrolog.ru/jour/article/view/643.

4. Rangaswami J, Chair V, Bhalla V, Blair JEA, Chang TI, Costa S et al. Cardiorenal syndrome: classification, pathophysiology, diagnosis, and treatment strategies: a scientific statement from the American Heart Association. Circulation. 2019;139(16):e840–e878. https://doi.org/10.1161/CIR.0000000000000664.

5. Davydov VV, Arekhina EL. Causes of development and progression of cardiorenal syndrome in heart failure patients. Prevention methods. Russian Journal of Cardiology. 2021;26(1):4160. (In Russ.) https://doi.org/10.15829/1560-4071-2021-4160.

6. Yang CW, Harris DCH, Luyckx VA, Nangaku M, Hou FF, Garcia GG et al. Global case studies of chronic kidney disease / treatment of end-stage kidney disease care. Kidney Int Suppl. 2020;10(1):e24–e48. https://doi.org/10.1016/j.kisu.2019.11.010.

7. GBD Chronic Kidney Disease Collaboration. Global, regional, and national burden of chronic kidney disease, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2020;10225(395):709–733. https://doi.org/10.1016/S0140-6736(20)30045-3.

8. Khayyat-Kholghi M, Oparil S, Davis BR, Tereshchenko LG. Worsening kidney function is the major mechanism of heart failure in hypertension: the ALLHAT study. JACC Heart Fail. 2021;9(2):100–111. https://doi.org/10.1016/j.jchf.2020.09.006.

9. Zarudskiy AA, Terekhina AA, Sergeeva YS, Gabdrakipova AA. Сhronic kidney disease and its role in cardiovascular risk assessment. Modern Problems of Science and Education. 2019;(4). (In Russ.) https://doi.org/10.17513/spno.29000.

10. Ndumele CE, Rangaswami J, Chow ShL, Neeland IJ, Tuttle KR, Khan SS et al. Cardiovascular-kidney-metabolic health: a presidential advisory from the American Heart Association. Circulation. 2023;148(20):1606–1635. https://doi.org/10.1161/CIR.0000000000001184.

11. Chumakova GA, Kuznetsova TYu, Druzhilov MA, Veselovskaya NG. Visceral adiposity as a global factor of cardiovascular risk. Russian Journal of Cardiology. 2018;(5):7–14. (In Russ.) https://doi.org/10.15829/1560-4071-2018-5-7-14.

12. Silveira RJL, Barbalho SM, Reverete de Araujo R, Bechara МD, Sloan RP, Sloan LA. Metabolic syndrome and cardiovascular diseases: Going beyond traditional risk factors. Diabetes Metab Res Rev. 2022;38(3):e3502. https://doi.org/10.1002/dmrr.3502.

13. Polozova EI, Puzanova EV, Seskina AA. Role of immunological disorders, endothelial dysfunction and hemostatic disorders in the genesis of arterial hypertension in the metabolic syndrome. Medical Immunology (Russia). 2020;22(2):221–230. (In Russ.) https://doi.org/10.15789/1563-0625-ROI-1926.

14. Koenen M, Hill MA, Cohen P, Sowers JR. Obesity, adipose tissue and vascular dysfunction. Circ Res. 2021;128(7):951–968. https://doi.org/10.1161/CIRCRESAHA.121.318093.

15. Polozova EI, Sorokina NN, Puzanova EV, Seskina AA. The role of metabolic disorders in the progression of renal dysfunction in patients with metabolic syndrome and arterial hypertension. Meditsinskiy Sovet. 2019;(6):170–175. (In Russ.) https://doi.org/10.21518/2079-701X-2019-6-170-175.

16. Coresh J, Heerspink HJL, Sang Y, Matsushita K, Arnlov J, Astor BC et al. Change in albuminuria and subsequent risk of end-stage kidney disease: an individual participant-level consortium meta-analysis of observational studies. Lancet Diabetes Endocrinol. 2019;7(2):115–127. https://doi.org/10.1016/S2213-8587(18)30313-9.

17. Chen HF, Xiao BJ, Chen LY, OuYang WW, Zhang X-L et al. Lipid parameters, adipose tissue distribution and prognosis prediction in chronic kidney Disease patients. Lipids Health Dis. 2024;23(1):5. https://doi.org/10.1186/s12944-024-02004-4.

18. Izmailova MY, Demidova TYu, Valentovich VV. Cardio-reno-мetabolic health: discussing the recommendations of the American Heart Association. FOCUS Endocrinology. 2024;5(2):35–45. (In Russ.) https://doi.org/10.62751/2713-0177-2024-5-2-16.

19. Mychka VB, Vertkin AL, Vardaev LI, Druzhilov MA, Ipatkin RV, Kalinkin AL et al. Experts’consensus on the interdisciplinary approach towards the management, diagnostics, and treatment of patients with metabolic syndrome. Cardiovascular Therapy and Prevention (Russian Federation). 2013;12(6):41–82. (In Russ.) https://cardiovascular.elpub.ru/jour/article/view/99/103.

20. Dedov II, Shestakova MV, Melnichenko GA, Mazurina NV, Andreeva EN, Bondarenko IZ et al. Interdisciplinary clinical practice guidelines “management of obesity and its comorbidities”. Obesity and Metabolism. 2021;18(1):5–99. (In Russ.) https://doi.org/10.14341/omet12714.

21. Chronic kidney disease (CKD). Nefrologiya. 2021;25(5):10–82. (In Russ.) Available at: https://journal.nephrolog.ru/jour/article/view/2024/1765.

22. Alprecht-Quiroz P, Zuniga-Pineda B, Lara-Teran JJ, Cáceres-Vinueza SV, Duerte-Vera YC. Cardiorenal syndrome: сlinical and echocardiographic aspects. Arch Cardiol Mex. 2020;90(4):503–510. https://doi.org/10.24875/CME.M20000156.

23. Ageev FT, Arutyunov GP, Begrambekova YuL, Belenkov YuN, Boytsov SA, Vasyuk YuA et al. 2020 Clinical practice guidelines for Chronic heart failure. Russian Journal of Cardiology. 2020;25(11):4083. (In Russ.) https://doi.org/10.15829/1560-4071-2020-4083.

24. Kozhevnikova MV, Belenkov YuN. Biomarkers in Heart Failure: Current and Future. Kardiologiya. 2021;61(5):4–16. (In Russ.) https://doi.org/10.18087/cardio.2021.5.n1530.

25. Pellicori Р, Zhang J, Cuthbert J, Urbinati А, Shah P, Kazmi S et al. Highly sensitive C-reactive protein in chronic heart failure: patient characteristics, phenotypes and method of death. Cardiovasc Res. 2020;116(1):91–100. https://doi.org/10.1093/cvr/cvz198.

26. Shutov AM, Efremova EV, Menzorov MV. Renal continuum: classification problems. Ulyanovsk Medico-Biological Journal. 2023;(1):43–49. (In Russ.) https://doi.org/10.34014/2227-1848-2023-1-43-49.

27. Lebedeva EN, Vyalkova AA, Afonina SN, Chesnokova SA. Dyslipidemia as a pathogenetic factor of the progression of the chronic kidney disease. Nephrology (Saint-Petersburg). 2019;23(5):56–64. (In Russ.) https://doi.org/10.24884/1561-6274-2019-23-5-56-64.

28. Zueva IB, Baratashvili GG, Krivonosov DS, Buch AV, Sidorkevich SV. The role of lipoprotein (a) in the development of cardiovascular events and the therapeutic potential. Arterial Hypertension (Russian Federation). 2016;22(3):232–243. (In Russ.) https://doi.org/10.18705/1607-419X2016-22-3-232-243.

29. Mach F, Baigent C, Catapano AL, Koskinas KС, Casula М, Badimon L et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020;1(41):111–188. https://doi.org/10.15829/1560-4071-2020-3826.

30. Chan DC, Watts GF. The Promise of PCSK9 and Lipoprotein(a) as Targets for Gene Silencing Therapies. Clin Ther. 2023;45(11):1034–1046. https://doi.org/10.1016/j.clinthera.2023.07.008.